Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Duong, Trinh ^a,b   Jourdain, Gonzague ^a,c,d   Ngo Giang Huong, Nicole ^a,c,d   Le Cœur, Sophie ^a,c,d   Kantipong, Pacharee ^e   Buranabanjasatean, Sudanee ^f   Leenasirimakul, Prattana ^g   Ariyadej, Sriprapar ^h   Tansuphasawasdikul, Somboon ⁱ   Thongpaen, Suchart ^j   Lallemant, Marc ^a,c,d  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e CHIANGRAI PRACHANUKROH HOSPITAL   (Thailand)

^f Mae Chan Hospital   (Thailand)

^g NAKORNPING HOSPITAL   (Thailand)

^h Rayong Hospital   (Thailand)

ⁱ BUDDHACHINARAJ HOSPITAL   (Thailand)

^j Mahasarakam Hospital   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS DEFINING EVENT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SURVIVAL; THAILAND; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; MALE; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; RISK; THAILAND; VIRAL LOAD;

EID: 84865054223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043375     Document Type: Article

References (38)

1. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. WHO Geneva.
2. Walker AS, Gibb DM, (2011) Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis 24: 27-33.
3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
4. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, etal (2007) Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 2483-2491.
5. Thai S, Koole O, Un P, Ros S, De Munter P, et al. (2009) Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 14: 1048-1058.
6. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
7. Russell EC, Charalambous S, Pemba L, Churchyard GJ, Grant AD, et al. (2010) Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health 10: 433.
8. Mills EJ, Bakanda C, Birungi J, Yaya S, Ford N (2012) The prognostic value of baseline CD4 cell count beyond 6 months of antiretroviral therapy in HIV positive patients in Uganda. AIDS.
9. Koenig SP, Rodriguez LA, Bartholomew C, Edwards A, Carmichael TE, et al. (2012) Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr 59: e60-71.
10. Weigel R, Estill J, Egger M, Harries AD, Makombe S, et al. (2012) Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 26: 365-373.
11. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, et al. (2012) Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr 59: e9-16.
12. Falster K, Choi JY, Donovan B, Duncombe C, Mulhall B, et al. (2009) AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 23: 2323-2336.
13. Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, et al. (2011) Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 58: 269-276.
14. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, et al. (2009) Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 23: 335-342.
15. Maman D, Pujades-Rodriguez M, Nicholas S, McGuire M, Szumilin E, et al. (2012) Response to antiretroviral therapy in sub-Saharan Africa: improved survival associated with CD4 above 500 cells/muL. AIDS 26: 1393-1398.
16. Moore DM, Yiannoutsos CT, Musick BS, Tappero J, Degerman R, et al. (2011) Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 58: 289-296.
17. Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, et al. (2004) Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 37: 1245-1252.
18. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, et al. (2002) A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 185: 178-187.
19. Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, et al. (2007) Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 21: 1867-1875.
20. Shah S, Smith CJ, Lampe F, Youle M, Johnson MA, et al. (2007) Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. HIV Med 8: 38-45.
21. Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, et al. (2004) Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS 18: 2419-2423.
22. Fregonese F, Collins IJ, Jourdain G, Le Coeur S, Cressey TR, et al. (2012) Predictors of 5-years mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr 60: 91-98.
23. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, et al. (2000) A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 343: 982-991.
24. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, et al. (2004) Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351: 217-228.
25. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. 2002. http://www.who.int/hiv/pub/prev_care/ScalingUp_E.pdf.
26. Mocroft A, Sterne JA, Egger M, May M, Grabar S, et al. (2009) Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 48: 1138-1151.
27. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, et al. (2000) Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356: 1800-1805.
28. Lanoy E, May M, Mocroft A, Phillip A, Justice A, et al. (2009) Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 23: 2199-2208.
29. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, et al. (2003) Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679-686.
30. Durrleman S, Simon R, (1989) Flexible regression models with cubic splines. Stat Med 8: 551-561.
31. Royston P, (2004) Multiple imputation of misisng data. Stata Journal 4: 227-241.
32. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, et al. (2007) HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 46: 72-77.
33. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, et al. (2009) Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 48: 787-794.
34. Babiker AG, Emery S, Fatkenheuer G, Gordin FM, Grund B, et al. (2012) Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials In press.
35. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, et al. (2008) Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 13: 959-967.
36. Lewis DK, Whitty CJ, Walsh AL, Epino H, Broek NR, et al. (2005) Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg 99: 561-567.
37. Kiragga AN, Castelnuovo B, Nakanjako D, Manabe YC, (2010) Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc 13: 42.
38. Phillips A, van Oosterhout J, (2010) DART points the way for HIV treatment programmes. Lancet 375: 96-98.